News

Aurobindo Pharma announced the receipt of the final approval from the US Food & Drug Administration (USFDA) to manufacture and market Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per mL, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Ravicti Oral Liquid 1.1 grams per mL, of Horizon Therapeutics U.S. Holding LLC. The product will be manufactured by Unit-III of the Company and will be launched immediately. The approved product has an estimated market size of US$ 50.2 million for the twelve months ending February 2026, according to IQVIA MAT. Aurobindo Pharma now has a total of 579 ANDA approvals (556 final approvals and 23 tentative approvals) from USFDA. Glycerol Phenylbutyrate Oral Liquid is indicated for use as a nitrogen-binding agent for chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.

The board of Aurobindo Pharma at its meeting held on 06 April 2026 has approved the transfer of the Company`s domestic branded generic pharmaceutical formulations products business on a going concern basis through a Business Transfer Agreement (BTA) to Auropharm (previously known as Auro Pharma), a wholly owned subsidiary of the Company. It is in line with the Company`s strategy in further streamlining and accelerating Company`s domestic business for faster growth.

The board of Aurobindo Pharma at its meeting held on 06 April 2026 has approved buyback of up to 54,23,728 fully paid up equity shares of face value of Re 1 each (0.93% of paid up equity share capital) at a price of Rs 1,475 per equity share payable in cash for an aggregate amount of Rs 800 crore.

Aurobindo Pharma will hold a meeting of the Board of Directors of the Company on 6 April 2026.

Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) inspected Unit-V, an API manufacturing facility, of Apitoria Pharma, a wholly owned subsidiary of the Company, situated at Industrial Development Area, Chemical Zone, Pashamylaram Village, Patancheru Mandal, Sangareddy District, 502307, Telangana from 01 December to 12 December 2025. At the end of the inspection, a `Form 483` was issued with 03 observations. The Unit has now received an Establishment Inspection Report (EIR) classifying the facility as `Voluntary Action Indicated` (VAI) and this inspection is now �closed�. Powered by Capital Market - Live News